The landscape of gynecological oncology has reached a significant milestone following the presentation of pivotal clinical trial data at the…
Read More
Navigating the Critical Transition from Laboratory Bench to GMP Fill-Finish CDMO Operations
The transition of a breakthrough therapeutic compound from an exploratory research laboratory to a clinical-grade Good Manufacturing Practice (GMP) environment…
Read More
ESMO 2026 Data Backs First-Line Orpathys Use in NSCLC Subgroup, But Adverse Events Temper Reaction
Recent clinical findings presented at the European Society for Medical Oncology (ESMO) Congress have shed new light on the therapeutic…
Read More
ESMO 2026: GSKs mo rez seeks an edge in a crowded adc field in ovarian cancer
The modern therapeutic landscape for advanced ovarian cancer is undergoing a profound structural evolution, driven largely by the clinical maturation…
Read More
ESMO 2026 Oral Cell Cycle Inhibitors Place Cyclin E1 as New Target in Oncology and Precision Medicine
The landscape of targeted cancer therapy is undergoing a significant paradigm shift following recent clinical disclosures at the European Society…
Read More
Pharma commercial vendor selection still runs on word of mouth and a Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the complex journey from clinical trial success to market entry, the final phase—commercialization—often represents the most…
Read More
Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers
The landscape of global research and development is undergoing a tectonic shift as the lines between Silicon Valley and the…
Read More
Pharma tariffs reach smaller drugmakers as industry warns of R&D pressure
The landscape of the American pharmaceutical industry underwent a significant structural shift on September 29, 2026, as the federal government…
Read More
Gilead Sciences Secures Global Rights to PepStar’s Oral IL-23 Receptor Inhibitor HCXT-2001 in Landmark $1.275bn Agreement
Gilead Sciences has significantly expanded its footprint in the immunology and inflammatory bowel disease (IBD) therapeutic landscapes through a multi-billion-dollar…
Read More
Egypt Reforms Obsolete Pharmaceutical Pricing Framework to Revitalize Domestic Healthcare Sector and Secure Essential Drug Supplies
Egypt has officially undertaken a comprehensive overhaul of its decades-old pharmaceutical pricing framework, a decisive policy shift designed to resolve…
Read More
